We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
-12.6%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$508M
AUM Growth
-$109M
Cap. Flow
+$26.4M
Cap. Flow %
5.19%
Top 10 Hldgs %
74.09%
Holding
34
New
7
Increased
6
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$25.1M
2
COGT icon
Cogent Biosciences
COGT
+$20.1M
3
GHRS icon
GH Research
GHRS
+$14.7M
4
INZY
Inozyme Pharma
INZY
+$11.8M
5
AKUS
Akouos Inc
AKUS
+$9.43M

Top Sells

Rank Stock Value
1
LONA
LeonaBio Inc
LONA
+$13.5M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$12.5M
3
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$12.2M
4
NUVL
Nuvalent
NUVL
+$11.2M
5
LENZ
LENZ Therapeutics
LENZ
+$8.22M

Sector Composition

Rank Sector Weight
1 Healthcare 96.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLYB icon
26
Rallybio
RLYB
$84.5M
$2.03M 0.4%
+33,567
New +$2.52M
XENE icon
27
Xenon Pharmaceuticals
XENE
$6.06B
$913K 0.18%
+30,000
New +$907K
LONA
28
LeonaBio Inc
LONA
$66.3M
– –
-100,000
Closed -$13.5M
ATXS
29
DELISTED
Astria Therapeutics
ATXS
– –
-538,999
Closed -$3.62M
CNTA
30
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-411,361
Closed -$3.69M
NUVL
31
DELISTED
Nuvalent
NUVL
– –
-803,951
Closed -$11.2M
LENZ
32
LENZ Therapeutics
LENZ
$166M
– –
-230,374
Closed -$8.22M
EIGR
33
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-48,992
Closed -$12.2M
SRRA
34
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-162,479
Closed -$5.21M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q2 2022 Portfolio in Review

As of Q2 2022, VR Adviser held 34 positions worth $508M, down 18% from $617M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

VR Adviser deployed $26.4M of net new capital in Q2 2022, opening 7 new positions and adding to 6 existing holdings. Its largest new stake was Inozyme Pharma: 2,709,987 shares worth $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Chinook Therapeutics, Inc. Common Stock, an estimated $12.5M trimmed.

  • VR Adviser's largest Q2 2022 buy was Inozyme Pharma: 2,709,987 shares worth $12.9M.
  • VR Adviser added most to Tricida, Inc. Common Stock in Q2 2022, an estimated $25.1M increase.
  • VR Adviser's biggest Q2 2022 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $12.5M.
  • VR Adviser fully exited LeonaBio Inc in Q2 2022, selling an estimated $13.5M.
  • VR Adviser's ten largest holdings make up 74% of its $508M portfolio in Q2 2022.
  • VR Adviser opened 7 new positions and closed 7 in Q2 2022.
  • VR Adviser's portfolio value fell 18% quarter-over-quarter to $508M.

Based on VR Adviser's 13F filing for Q2 2022, filed 15 Aug 2022.